ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

China homegrown COVID pill included in national subsidy program

Price negotiations with Pfizer break down over more expensive Paxlovid

China approved Genuine Biotech’s Azvudine for adults with normal COVID symptoms under an emergency use authorization plan in July 2022.

China's homegrown COVID antiviral pill was included in the nation's medical subsidy program, health authorities said, after pricing talks broke down with Pfizer Inc. to cover its more expensive Paxlovid.

Azvudine, developed by Henan-based Genuine Biotech, will be priced at 11.58 yuan ($1.71) per pill, and a box of 35 will be 175 yuan, compared with 1,890 yuan ($279) to 2,300 yuan for a five-day course of 30 Paxlovid pills, according to the National Health Commission.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more